Cargando…

Cirrhotic portal hypertension: From pathophysiology to novel therapeutics

Portal hypertension and bleeding from gastroesophageal varices is the major cause of morbidity and mortality in patients with cirrhosis. Portal hypertension is initiated by increased intrahepatic vascular resistance and a hyperdynamic circulatory state. The latter is characterized by a high cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gunarathne, Lakmie S, Rajapaksha, Harinda, Shackel, Nicholas, Angus, Peter W, Herath, Chandana B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596642/ https://www.ncbi.nlm.nih.gov/pubmed/33177789 http://dx.doi.org/10.3748/wjg.v26.i40.6111

Ejemplares similares

Mas‐related G protein‐coupled receptor type D antagonism improves portal hypertension in cirrhotic rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2022)

Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats
por: Gunarathne, Lakmie S., et al.
Publicado: (2019)

Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options
por: Rajapaksha, Indu G., et al.
Publicado: (2021)

Liver‐Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug‐Resistant Gene 2‐Knockout Mice
por: Rajapaksha, Indu G., et al.
Publicado: (2019)

Editorial: Portal Hypertension in Cirrhosis: From Pathogenesis to Novel Treatments
por: Herath, Chandana B., et al.
Publicado: (2022)

Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver
por: Rajapaksha, Indu G., et al.
Publicado: (2021)

Current therapies and novel approaches for biliary diseases
por: Rajapaksha, Indu G, et al.
Publicado: (2019)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020)

Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension
por: Biecker, Erwin
Publicado: (2013)

Causes and Management of Non-cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2020)

Pathophysiology of Portal Hypertension
por: Morales-Ruiz, Manuel, et al.
Publicado: (2015)

Wall shear stress in portal vein of cirrhotic patients with portal hypertension
por: Wei, Wei, et al.
Publicado: (2017)

The Impact of Partial Splenic Embolization on Portal Hypertensive Gastropathy in Cirrhotic Patients with Portal Hypertension
por: Saeki, Michio, et al.
Publicado: (2023)

Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension
por: Uschner, Frank E., et al.
Publicado: (2015)

Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension
por: Klein, Sabine, et al.
Publicado: (2016)

Cardiac dysfunction in cirrhotic portal hypertension with or without ascites
por: Dadhich, Sunil, et al.
Publicado: (2014)

Idiopathic non-cirrhotic portal hypertension: a review
por: Schouten, Jeoffrey NL, et al.
Publicado: (2015)

The beneficial effects of curcumin in cirrhotic rats with portal hypertension
por: Hsu, Shao-Jung, et al.
Publicado: (2017)

Research progress on signaling pathways in cirrhotic portal hypertension
por: Xu, Wen, et al.
Publicado: (2018)

Non-cirrhotic portal hypertension in an ankylosing spondylitis patient
por: Park, Sukki, et al.
Publicado: (2018)

Non-Cirrhotic Portal Hypertension in Systemic Lupus Erythematosus
por: Suárez-Díaz, Silvia, et al.
Publicado: (2023)

Antibody and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and therapeutic principles
por: Zhang, Kun, et al.
Publicado: (2022)

Portal hypertension: pathophysiology and treatment

Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension: a case report: Splenic arteriovenous fistula leading to non-cirrhotic portal hypertension
por: Abou Yassine, Ahmad, et al.
Publicado: (2023)

In Silico Structural Homology Modelling and Docking for Assessment of Pandemic Potential of a Novel H7N9 Influenza Virus and Its Ability to Be Neutralized by Existing Anti-Hemagglutinin Antibodies
por: Rajapaksha, Harinda, et al.
Publicado: (2014)

Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension
por: MUTI, LEON ADRIAN, et al.
Publicado: (2015)

Pathological abnormalities in splenic vasculature in non-cirrhotic portal hypertension: Its relevance in the management of portal hypertension
por: Gupta, Shahana, et al.
Publicado: (2020)

Non-cirrhotic portal vein thrombosis – therapeutic challenge
por: Sarquis, Lucas Mansano, et al.
Publicado: (2022)

Chronic Myeloid Leukemia Presenting as Non-cirrhotic Portal Hypertension
por: Gemnani, Rinkle R, et al.
Publicado: (2023)

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Pathophysiology of Portal Hypertension and Esophageal Varices
por: Maruyama, Hitoshi, et al.
Publicado: (2012)

Blood Ammonia Level Correlates with Severity of Cirrhotic Portal Hypertensive Gastropathy
por: El-Kalla, Ferial, et al.
Publicado: (2018)

Systemic Mastocytosis Complicated by Non-Cirrhotic Portal Hypertension and Variceal Bleeding
por: McCarty, Thomas R., et al.
Publicado: (2017)

Laparoscopic selective esophagogastric devascularization and splenectomy for patients with cirrhotic portal hypertension
por: Lin, Jie, et al.
Publicado: (2018)

Interobserver study on histologic features of idiopathic non-cirrhotic portal hypertension
por: Kmeid, Michel, et al.
Publicado: (2020)

Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension
por: Gioia, Stefania, et al.
Publicado: (2021)

Progressive dyspnoea in a patient with idiopathic non-cirrhotic portal hypertension
por: Cullivan, Sarah, et al.
Publicado: (2022)

Pregnancy in Patients with Non-cirrhotic Portal Hypertension: A Literature Review
por: Giri, Suprabhat, et al.
Publicado: (2022)

The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice
por: Rajapaksha, Indu G., et al.
Publicado: (2018)

Association Between Portal Vein Color Doppler Findings and the Severity of Disease in Cirrhotic Patients With Portal Hypertension
por: Mittal, Puneet, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hj7ok5qqg0fr561g0517nuud3u